Kazia Therapeutics LTD Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Kazia Therapeutics reports a board-approved award of 100,000 stock options to Director Steven R. S. Coffey.
NASDAQ
Kazia Therapeutics reports on the grant of stock options and restricted share units to its CEO, John E. Friend II, with vesting schedules extending over several years.
NASDAQ
Kazia Therapeutics reports the grant of 150,000 stock options to VP, Finance and Controller Jeffrey Bonacorda, with specific vesting and exercise terms.
NASDAQ
Kazia Therapeutics reports a director, Ebru Davidson, was granted 100,000 stock options with an exercise price of $9.10 per ADS, vesting in January 2027.
NASDAQ
Kazia Therapeutics reports a grant of 100,000 stock options to Director, CMC David Cain, with an exercise price of $9.10 per ADS.
NASDAQ
Kazia Therapeutics reports a board-approved award of 75,000 stock options to Director Robert F. Apple.